← Leaderboards
James E Kirby
Beth Israel Deaconess Medical Center
$9,890,264
Attributed
$15,362,333
Total exposure
16
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,362,333 · 16
By mechanism
R01$8,939,070 · 3
R21$4,613,257 · 10
R33$1,505,792 · 1
R03$182,984 · 1
K08$121,230 · 1
Top collaborators
- George A O'Doherty10 shared
- Edward W Yu9 shared
- Roman Manetsch7 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Thea Brennan-Krohn$2,347,967
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionPathogenResistanceBaseAntimicrobialAntibiotic ResistanceAnalogAntibioticsIn VivoCarbapenem-Resistant EnterobacteriaceaeMulti-Drug ResistancePharmaceutical PreparationsMetabolicStructure-Activity RelationshipPharmaceutical ChemistryOrganismPropertyLaboratoriesFrequenciesScaffoldMaximum Tolerated DoseNovel TherapeuticsTherapeutic EffectCenters For Disease Control And Prevention (U.S.)
Grant awards (40)
Development and Characterization of Phage QBeta-Based SARS-CoV-2 RT-qPCR Assay Calibration Standards$251,570
R21 · FY2025 · AI · contact PI
Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials$761,258
R01 · FY2024 · AI · contact PI
Development and Characterization of Phage QBeta-Based SARS-CoV-2 RT-qPCR Assay Calibration Standards$216,125
R21 · FY2024 · AI · contact PI
Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials$766,825
R01 · FY2023 · AI · contact PI
De Novo Synthesis, and Functional and Structural Characterization of Novel Aminoglycoside Analogues to Bypass Resistance Mechanisms and Optimize Selectivity$757,156
R01 · FY2023 · AI · contact PI
Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials$772,231
R01 · FY2022 · AI · contact PI
De Novo Synthesis, and Functional and Structural Characterization of Novel Aminoglycoside Analogues to Bypass Resistance Mechanisms and Optimize Selectivity$765,318
R01 · FY2022 · AI · contact PI
Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials$777,478
R01 · FY2021 · AI · contact PI
De Novo Synthesis, and Functional and Structural Characterization of Novel Aminoglycoside Analogues to Bypass Resistance Mechanisms and Optimize Selectivity$772,551
R01 · FY2021 · AI · contact PI
Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials$818,324
R01 · FY2020 · AI · contact PI
De Novo Synthesis, and Functional and Structural Characterization of Novel Aminoglycoside Analogues to Bypass Resistance Mechanisms and Optimize Selectivity$815,399
R01 · FY2020 · AI · contact PI
Development of Streptothricin Class Antimicrobials as Novel Therapeutics$248,169
R21 · FY2020 · AI
Apramycin scaffold exploration using novel glycochemistry and SAR studies to enhance activity against Acinetobacter baumannii and other multidrug-resistant Gram-negative pathogens$210,119
R21 · FY2020 · AI · contact PI
Fusidic acid derivatization to enhance entry into Gram-negative pathogens$209,030
R21 · FY2020 · AI · contact PI
Targeted modification of the apramycin 2-deoxystreptamine ring to block aminoglycoside modifying enzyme-based inactivation and enhance potency against multidrug-resistant Gram-negative pathogens$82,117
R03 · FY2020 · AI · contact PI
Plasmid Eviction to Restore Susceptibility in Carbapenem-Resistant Enterobacteriaceae$521,998
R33 · FY2019 · AI · contact PI
Apramycin scaffold exploration using novel glycochemistry and SAR studies to enhance activity against Acinetobacter baumannii and other multidrug-resistant Gram-negative pathogens$266,324
R21 · FY2019 · AI · contact PI
Fusidic acid derivatization to enhance entry into Gram-negative pathogens$266,130
R21 · FY2019 · AI · contact PI
Microscopy-Based Antimicrobial Susceptibility Testing (MAST)$223,354
R21 · FY2019 · AI · contact PI
Development of Streptothricin Class Antimicrobials as Novel Therapeutics$219,329
R21 · FY2019 · AI
Targeted modification of the apramycin 2-deoxystreptamine ring to block aminoglycoside modifying enzyme-based inactivation and enhance potency against multidrug-resistant Gram-negative pathogens$100,867
R03 · FY2019 · AI · contact PI
Plasmid Eviction to Restore Susceptibility in Carbapenem-Resistant Enterobacteriaceae$521,998
R33 · FY2018 · AI · contact PI
Microscopy-Based Antimicrobial Susceptibility Testing (MAST)$263,805
R21 · FY2018 · AI · contact PI
Plasmid Eviction to Restore Susceptibility in Carbapenem-Resistant Enterobacteriaceae$461,796
R33 · FY2017 · AI · contact PI
Novel Antimicrobials Targeting Bacterial Type IV Secretion Systems$391,500
R01 · FY2016 · AI · contact PI
VALIDATION OF A HIGH THROUGHPUT SCREEN FOR KPC PLASMID EVICTION$261,000
R21 · FY2016 · AI · contact PI
Plasmid Eviction to Restore Susceptibility in Carbapenem-Resistant Enterobacteriaceae$174,000
R21 · FY2016 · AI · contact PI
Novel Antimicrobials Targeting Bacterial Type IV Secretion Systems$391,500
R01 · FY2015 · AI · contact PI
VALIDATION OF A HIGH THROUGHPUT SCREEN FOR KPC PLASMID EVICTION$217,500
R21 · FY2015 · AI · contact PI
Plasmid Eviction to Restore Susceptibility in Carbapenem-Resistant Enterobacteriaceae$130,500
R21 · FY2015 · AI · contact PI
Novel Antimicrobials Targeting Bacterial Type IV Secretion Systems$391,500
R01 · FY2014 · AI · contact PI
Novel Antimicrobials Targeting Bacterial Type IV Secretion Systems$368,010
R01 · FY2013 · AI · contact PI
Novel Antimicrobials Targeting Bacterial Type IV Secretion Systems$390,020
R01 · FY2012 · AI · contact PI
Type IV Secretion System Therapeutics$258,390
R21 · FY2011 · AI · contact PI
Type IV Secretion System Therapeutics$217,135
R21 · FY2010 · AI · contact PI
Non-Antibiotic Selectable Markers for Bacillus Anthracis$348,270
R21 · FY2009 · AI · contact PI
Non-Antibiotic Selectable Markers for Bacillus Anthracis$212,500
R21 · FY2008 · AI · contact PI
The Basis of Anthrax-Induced Vascular Damage$207,507
R21 · FY2006 · AI · contact PI
The Basis of Anthrax-Induced Vascular Damage$212,500
R21 · FY2005 · AI
LEGIONELLA PNEUMOPHILA VIRULENCE FACTORS DEFINED IN VIVO$121,230
K08 · FY2000 · AI